Natera (NASDAQ:NTRA) Issues Earnings Results

Natera (NASDAQ:NTRA) announced its quarterly earnings data on Tuesday. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31, Briefing.com reports. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the previous year, the company earned ($0.95) EPS. The firm’s revenue for the quarter was up 63.9% compared to the same quarter last year. Natera updated its FY 2024 guidance to EPS.

Natera Trading Up 0.9 %

Shares of NTRA opened at $135.12 on Wednesday. The stock has a fifty day moving average of $125.09 and a two-hundred day moving average of $114.52. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company has a market capitalization of $16.71 billion, a PE ratio of -55.15 and a beta of 1.53. Natera has a fifty-two week low of $46.96 and a fifty-two week high of $140.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NTRA shares. UBS Group reduced their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. TD Cowen lifted their price target on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. The Goldman Sachs Group lifted their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Robert W. Baird lifted their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Sanford C. Bernstein lifted their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $129.13.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,583 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the transaction, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Natera news, CEO Steven Leonard Chapman sold 5,583 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the transaction, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 608 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08. Following the sale, the chief financial officer now directly owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 47,464 shares of company stock worth $5,849,977. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.